Anemia and cardiovascular disease in diabetic nephropathy

被引：32

作者：

McFarlane S.I. ^{[1
]}

Salifu M.O. ^{[1
]}

Makaryus J. ^{[1
]}

Sowers J.R. ^{[1
]}

机构：

[1] Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, State University of New York Health Science Center at Brooklyn, Brooklyn, NY 11203-2098

来源：

Current Diabetes Reports | 2006年 / 6卷 / 3期

关键词：

Anemia; Chronic Kidney Disease; Diabetic Nephropathy; Darbepoetin Alfa; Nephrol Dial Transplant;

D O I：

10.1007/s11892-006-0037-4

中图分类号：

学科分类号：

摘要：

Cardiovascular disease (CVD) is the major cause of morbidity and mortality in people with diabetes and in those with chronic kidney disease (CKD). Diabetes, occurring in epidemic proportions in the United States and worldwide, is also the leading cause of CKD and kidney failure. Identification of modifiable risk factors for CVD in patients with diabetes and CKD is thus of paramount importance. Anemia is increasingly recognized as a potential CVD risk factor in patients with diabetic nephropathy, in whom it is generally more severe and occurs at an earlier stage of CKD. In this review, we discuss the epidemiologic evidence, pathophysiologic mechanisms, and the current research findings, highlighting the role of anemia as a potential modifiable risk factor for CVD in patients with diabetic nephropathy, a particularly vulnerable population for CVD. Copyright © 2006 by Current Science Inc.

引用

页码：213 / 218

页数：5

共 53 条

[1]

Mokdad A.H., Ford E.S., Bowman B.A., Et al., The continuing increase of diabetes in the US, Diabetes Care, 24, (2001)

[2]

Hogan P., Dall T., Nikolov P., Economic costs of diabetes in the US in 2002, Diabetes Care, 26, pp. 917-932, (2003)

[3]

Boyle J.P., Honeycutt A.A., Narayan K.M., Et al., Projection of diabetes burden through 2050: Impact of changing demography and disease prevalence in the U.S, Diabetes Care, 24, pp. 1936-1940, (2001)

[4]

Grundy S.M., Benjamin I.J., Burke G.L., Et al., Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association, Circulation, 100, pp. 1134-1146, (1999)

[5]

McFarlane S.I., Banerji M., Sowers J.R., Insulin resistance and cardiovascular disease, J Clin Endocrinol Metab, 86, pp. 713-718, (2001)

[6]

Blendea M.C., McFarlane S.I., Isenovic E.R., Et al., Heart disease in diabetic patients, Curr Diab Rep, 3, pp. 223-229, (2003)

[7]

Sarnak M.J., Cardiovascular complications in chronic kidney disease, Am J Kidney Dis, 41, 5 SUPPL., pp. 11-17, (2003)

[8]

Levin A., Djurdjev O., Barrett B., Et al., Cardiovascular disease in patients with chronic kidney disease: Getting to the heart of the matter, Am J Kidney Dis, 38, pp. 1398-1407, (2001)

[9]

Culleton B.F., Larson M.G., Wilson P.W., Et al., Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency, Kidney Int, 56, pp. 2214-2219, (1999)

[10]

Vlagopoulos P.T., Sarnak M.J., Traditional and nontraditional cardiovascular risk factors in chronic kidney disease, Med Clin North Am, 89, pp. 587-611, (2005)

← 1 2 3 4 5 6 →